Stay updated with breaking news from Simcere Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Shanghai Fosun Pharma announced it has licensed US rights to a PD-1 candidate from its longstanding partner Henlius Biotech in an $840 million agreement. Read more here...
Beijing YishengBio will merge with SPAC vehicle Summit Healthcare Acquisition to list on Nasdaq. Sihuan Pharma subsidiary Xuanzhu Biopharm has filed for an IPO on the Shanghai STAR Exchange.
Frontera Therapeutics completed a $160 million Series B funding to support its AAV programs.